From: CTHRC1 is a prognosis-related biomarker correlated with immune infiltrates in colon adenocarcinoma
Description | Gen markers | COAD | |||
---|---|---|---|---|---|
None | Purity | ||||
Cor | p | Cor | p | ||
B cell | CD19 | 0.204084 | 1.07E-05 | 0.204084 | 1.07E-05 |
CD79A | 0.285476 | 4.89E-10 | 0.285476 | 4.89E-10 | |
T cell (general) | CD3D | 0.292765 | 1.67E-10 | 0.292765 | 1.67E-10 |
CD3E | 0.367829 | 4.04E-16 | 0.367829 | 4.04E-16 | |
CD2 | 0.383322 | 1.77E-17 | 0.383322 | 1.77E-17 | |
CD8+T cell | CD8A | 0.346485 | 2.30E-14 | 0.346485 | 2.30E-14 |
CD8B | 0.215771 | 3.16E-06 | 0.215771 | 3.16E-06 | |
CD86 | 0.686509 | 4.24E-65 | 0.686509 | 4.24E-65 | |
CSF1R | 0.585082 | 2.04E-43 | 0.585082 | 2.04E-43 | |
TAM | CCL2 | 0.710411 | 1.42E-71 | 0.710411 | 1.42E-71 |
CD68 | 0.467805 | 2.78E-26 | 0.467805 | 2.78E-26 | |
IL10 | 0.512319 | 5.17E-32 | 0.512319 | 5.17E-32 | |
M1 macrophage | IRF5 | 0.308985 | 1.37E-11 | 0.308985 | 1.37E-11 |
PTGS2 | 0.289882 | 2.56E-10 | 0.289882 | 2.56E-10 | |
NOS2 | -0.2026 | 1.25E-05 | -0.2026 | 1.25E-05 | |
M2 macrophage | CD163 | 0.679957 | 1.97E-63 | 0.679957 | 1.97E-63 |
VSIG4 | 0.658727 | 2.56E-58 | 0.658727 | 2.56E-58 | |
MS4A4A | 0.662905 | 2.72E-59 | 0.662905 | 2.72E-59 | |
Neutrophils | CEACAM8 | -0.18625 | 6.07E-05 | -0.18625 | 6.07E-05 |
ITGAM | 0.670462 | 4.31E-61 | 0.670462 | 4.31E-61 | |
CCR7 | 0.311286 | 9.52E-12 | 0.311286 | 9.52E-12 | |
Natural killer cell | KIR2DL1 | 0.196671 | 2.25E-05 | 0.196671 | 2.25E-05 |
KIR2DL3 | 0.160361 | 0.000571 | 0.160361 | 0.000571 | |
KIR2DL4 | 0.19043 | 4.10E-05 | 0.19043 | 4.10E-05 | |
KIR3DL1 | 0.225887 | 1.04E-06 | 0.225887 | 1.04E-06 | |
KIR3DL2 | 0.207018 | 7.94E-06 | 0.207018 | 7.94E-06 | |
KIR3DL3 | 0.052956 | 0.258054 | 0.052956 | 0.258054 | |
KIR2DS4 | 0.168361 | 0.000296 | 0.168361 | 0.000296 | |
Dendritic cell | HLA-DPB1 | 0.504539 | 5.98E-31 | 0.504539 | 5.98E-31 |
HLA-DQB1 | 0.32912 | 4.95E-13 | 0.32912 | 4.95E-13 | |
HLA-DRA | 0.507051 | 2.73E-31 | 0.507051 | 2.73E-31 | |
HLA-DPA1 | 0.513432 | 3.63E-32 | 0.513432 | 3.63E-32 |